TOTUM•63 is a unique patented combination of five plant extracts, specifically designed to target a number of pathophysiological mechanisms of type 2 diabetes.
The first product to be clinically proven in prediabetic subjects
14 communications at international scientific congresses since 2016, including 11 selections by the three main global diabetes congresses: American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), and the International Diabetes Federation (IDF).
4 first scientific papers published by international journals since 2021: a first set of preclinical and clinical results on TOTUM•63 published, as part of a comprehensive publication plan for this active substance.